The Burrill Report


The Burrill Report (November 28, 2011): Will Alnylam Results Reignite Fervor for RNAi (.MP3,12.74 Mb)

Preliminary results in a small, early-stage trial don’t usually generate a lot of excitement, but Alnylam Pharmaceuticals says it believes it has shown its experimental RNAi therapy to treat a rare genetic disorder marks the first time that RNAi has been shown to silence a disease-causing gene in humans. Though the technology generated much excitement among large pharmaceutical companies several years ago, RNAi fell out of favor as it proved difficult to deliver the therapy to targets within the body. We spoke to Barry Greene, president and COO for Alnylam, about the results, how it advances the company’s efforts to remake itself into a product rather than a platform company, and what it will take to once again capture the imagination of investors and pharmaceutical companies.











November 23, 2011
http://www.burrillreport.com/article-will_alnylams_results_reignite_fervor_for_rnai.html